Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis
- PMID: 11291106
- PMCID: PMC6807797
- DOI: 10.1002/jcla.2
Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis
Abstract
The kidney is an important site of endothelin-1 (ET-1) production and is particularly susceptible to ET-1 action. Infusion of ET-1 in rats induces both functional and morphological alterations in the kidneys. Increased plasma level of ET-1 has been reported in patients with chronic renal failure. However, there are still no reports on the plasma and urinary ET-1 levels in patients with focal segmental glomerulosclerosis (FSGS). In the present study, we have measured the plasma concentration and urinary excretion rate of ET-1 in 15 patients with nephrotic syndrome due to FSGS, and observed the serial changes of plasma and urinary ET-1 in nephrotic rats with FSGS, induced by repeated injection with puromycin aminonucleoside (PAN). ET-1 was measured with radioimmunoassay. The results showed that plasma ET-1 concentration in FSGS patients was significantly higher than in normal controls (P < 0.05), and that urinary ET-1 excretion rate was also significantly higher in FSGS patients than in normal controls (P < 0.01). In FSGS patients, the plasma and urinary ET-1 was significantly correlated (P < 0.05), and the urinary ET-1 excretion rate was significantly correlated with the amount of proteinuria (P < 0.05) and the glomerular sclerosing score (P < 0.01). In the ten rats with PAN-induced FSGS, serial examination showed a significant increase in plasma ET-1 after 8 weeks of injections, while the urinary ET-1 excretion rate showed a biphasic increase that showed a peak after 4 to 6 weeks. The same changes in plasma and urinary ET-1 levels were not observed in control rats injected with normal saline at the same frequency. Our results suggest that ET-1 may be involved in the pathogenesis of FSGS in both humans and rats.
References
-
- Yanagisawa M, Kurihara H, Kimura S. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415. - PubMed
-
- Kohan DE. 1998. Angiotensin II and endothelin in chronic glomerulonephritis. Kidney Int 54:646–647. - PubMed
-
- Herman WH, Emancipator SN, Rhoten RLP, Simonson MS. 1998. Vascular and glomerular expression of endothelin‐1 in normal human kidney. Am J Physiol 275:F8–F17. - PubMed
-
- Brochu E, Lacasse S, Moreau C, et al. 1999. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant 14:1881–1888. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
